SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt sprints after UK regulator eases restriction on its Daman manufacturing facility

07 Nov 2013 Evaluate

Wockhardt is currently trading at Rs. 515.55, up by 45.10 points or 9.59% from its previous closing of Rs. 470.45 on the BSE.

The scrip opened at Rs. 481.90 and has touched a high and low of Rs. 524.00 and Rs. 481.90 respectively. So far 598972 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2166.05 on 12-Mar-2013 and a 52 week low of Rs. 344.15 on 08-Aug-2013.

Last one week high and low of the scrip stood at Rs. 470.45 and Rs. 443.00 respectively. The current market cap of the company is Rs. 5473.29 crore.

The promoters holding in the company stood at 73.88% while Institutions and Non-Institutions held 10.73% and 15.25% respectively.

Wockhardt has received a communication from the Medicines and Healthcare Products Regulatory Agency, United Kingdom (UKMHRA), whereby the agency has allowed the company to manufacture and supply most of the products manufactured at Survey No 406/4-5-7, Kadaiya, Nani Daman facility and assessed to be critical to public health.

The company had earlier on October 22, 2013 received communication from UKMHRA, whereby the agency had decided to withdraw the previously issued GMP Certificate to the said manufacturing facility.

As a result the net impact on the annualised consolidated revenue is expected to be less than Euro 1 million, out of the total annual consolidated revenue of approximately  Euro 18 million, from the said facility.

Wockhardt Share Price

1396.80 37.70 (2.77%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×